MX2014002204A - Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma. - Google Patents

Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma.

Info

Publication number
MX2014002204A
MX2014002204A MX2014002204A MX2014002204A MX2014002204A MX 2014002204 A MX2014002204 A MX 2014002204A MX 2014002204 A MX2014002204 A MX 2014002204A MX 2014002204 A MX2014002204 A MX 2014002204A MX 2014002204 A MX2014002204 A MX 2014002204A
Authority
MX
Mexico
Prior art keywords
reducing
immunoglobulin composition
plasma
derived immunoglobulin
factor
Prior art date
Application number
MX2014002204A
Other languages
English (en)
Other versions
MX349005B (es
Inventor
Hans-Peter Schwarz
Wolfgang Teschner
Harald Arno Butterweck
Bernhard Koelbl
Lucia Hofbauer
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of MX2014002204A publication Critical patent/MX2014002204A/es
Publication of MX349005B publication Critical patent/MX349005B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención describe métodos para reducir la actividad amidolítica y anti-complemento (ACA) de una composición de inmunoglobulina a través del uso de cromatografía de intercambio catiónico. En una modalidad específica, la invención provee métodos para reducir el contenido de Factor XI y/o Factor XIa y/o ACA en una composición de inmunoglobulina por recolección la porción principal de un eluato de intercambio catiónico. La presente invención también provee una composición de inmunoglobulina con niveles reducidos de actividad amidolítica, Factor XI y/o Factor XIa y/o ACA.
MX2014002204A 2011-08-26 2012-08-27 Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma. MX349005B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161527974P 2011-08-26 2011-08-26
PCT/US2012/052567 WO2013033042A1 (en) 2011-08-26 2012-08-27 Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition

Publications (2)

Publication Number Publication Date
MX2014002204A true MX2014002204A (es) 2014-06-11
MX349005B MX349005B (es) 2017-07-06

Family

ID=46970397

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002204A MX349005B (es) 2011-08-26 2012-08-27 Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma.

Country Status (20)

Country Link
US (1) US9403899B2 (es)
EP (1) EP2748193B1 (es)
JP (1) JP6165143B2 (es)
KR (1) KR101949553B1 (es)
CN (1) CN103874708B (es)
AR (1) AR087953A1 (es)
AU (1) AU2012300220C1 (es)
BR (1) BR112014004445B1 (es)
CA (1) CA2846599A1 (es)
CL (1) CL2014000480A1 (es)
CO (1) CO6920256A2 (es)
EA (1) EA030251B1 (es)
ES (1) ES2624485T3 (es)
HK (1) HK1199267A1 (es)
IL (1) IL231083B (es)
MX (1) MX349005B (es)
MY (1) MY165164A (es)
SG (1) SG11201400233TA (es)
TW (1) TWI610937B (es)
WO (1) WO2013033042A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
ES2785375T3 (es) 2014-03-11 2020-10-06 Green Cross Holdings Corp Procedimiento de purificación de inmunoglobulina
CA2941232C (en) * 2014-03-11 2020-08-25 Green Cross Holdings Corporation Method for purifying immunoglobulin
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
KR101941974B1 (ko) * 2016-11-18 2019-01-24 주식회사 녹십자 혈장 단백질 정제시 fxi의 제거방법
EP3638693A4 (en) * 2017-06-12 2021-04-14 Kamada Ltd IMMUNOGLOBULIN COMPOSITIONS AND PROCESS FOR THEIR PREPARATION
WO2023215722A1 (en) * 2022-05-02 2023-11-09 Takeda Pharmaceutical Company Limited Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (es) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
JPS5598117A (en) 1979-01-17 1980-07-25 Chemo Sero Therapeut Res Inst Purification of gamma-globulin derivative
US4639513A (en) 1984-02-02 1987-01-27 Cuno Inc. Intravenously injectable immunoglobulin G (IGG) and method for producing same
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US4482483A (en) 1983-04-06 1984-11-13 Armour Pharmceutical Company Composition of intravenous immune globulin
DE3483784D1 (de) 1984-07-07 1991-01-31 Woelm Pharma Gmbh & Co Verfahren zur herstellung von gamma-globulin zur intravenoesen anwendung.
DE3640513A1 (de) 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
DE3641115A1 (de) 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
ES2129076T5 (es) 1993-12-27 2003-05-16 Zlb Bioplasma Ag Procedimiento para la preparacion de un concentrado de inmunoglobulina g anti-d y composicion farmaceutica que lo contiene.
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6162904A (en) 1997-12-24 2000-12-19 Alpha Therapeutic Corporation Manufacturing method for intraveneously administrable immune globulin and resultant product
KR100501263B1 (ko) * 1998-06-09 2005-07-18 스태튼스 세룸 인스티튜트 정맥 주사용 면역글로불린의 제조 방법 및 그 외의 면역글로불린 제품
ES2527915T3 (es) * 1998-06-09 2015-02-02 Csl Behring Ag Producto de inmunoglobulina G (IgG) líquido
SE0001128D0 (sv) * 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
EA023382B1 (ru) * 2009-05-27 2016-05-31 Бакстер Интернэшнл Инк. Способ получения высококонцентрированного препарата иммуноглобулина для подкожного применения
IL212911A0 (en) 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof

Also Published As

Publication number Publication date
MX349005B (es) 2017-07-06
CL2014000480A1 (es) 2014-10-03
IL231083B (en) 2019-06-30
JP2014525417A (ja) 2014-09-29
BR112014004445A2 (pt) 2017-03-28
TW201326192A (zh) 2013-07-01
US20130058961A1 (en) 2013-03-07
IL231083A0 (en) 2014-03-31
CO6920256A2 (es) 2014-04-10
ES2624485T3 (es) 2017-07-14
TWI610937B (zh) 2018-01-11
US9403899B2 (en) 2016-08-02
AU2012300220A1 (en) 2013-05-02
EP2748193B1 (en) 2017-02-01
KR101949553B1 (ko) 2019-02-18
EP2748193A1 (en) 2014-07-02
CA2846599A1 (en) 2013-03-07
EA201400273A1 (ru) 2014-08-29
AR087953A1 (es) 2014-04-30
CN103874708B (zh) 2018-07-10
AU2012300220C1 (en) 2016-11-10
AU2012300220B2 (en) 2015-09-10
JP6165143B2 (ja) 2017-07-19
HK1199267A1 (en) 2015-06-26
KR20140062088A (ko) 2014-05-22
SG11201400233TA (en) 2014-08-28
EA030251B1 (ru) 2018-07-31
MY165164A (en) 2018-02-28
BR112014004445B1 (pt) 2022-11-22
WO2013033042A1 (en) 2013-03-07
CN103874708A (zh) 2014-06-18

Similar Documents

Publication Publication Date Title
MX349005B (es) Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma.
PH12014501108A1 (en) Anti-il-36r antibodies
IN2013MU02145A (es)
MX2018013128A (es) Molecula de union al antigeno para promover la perdia de antigeno a traves de fc gamma riib.
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
MX2019008065A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
MX343858B (es) Anticuerpos anti-il-23.
NZ605400A (en) Chimeric clotting factors
MX2013010019A (es) Metodo para aislamiento de osteopontina utilizando alimentos concentrados.
MX342920B (es) Metodo para purificar polipeptidos o inmunoconjugados activos.
MX368653B (es) Anticuerpos anti-il-23p19.
MX2014000531A (es) Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
PH12016500158A1 (en) Methods for controlling fucosylation levels in proteins
SG10201907901XA (en) Antibodies, uses & methods
SG10201804952QA (en) Glucosylceramide synthase inhibitors
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
MY170869A (en) Chuck for chemical vapor deposition systems and related methods therefor
WO2013187971A3 (en) Macrocycles
NZ716205A (en) Purification process for pth
MX351465B (es) Un método para remover nitrógeno de amonio de agua con residuos orgánicos.
MX341733B (es) Purificacion de inhibidor de proteasa alfa1 derivado de cultivo celular.
UA74021U (ru) Способ лечения хронического вирусного гепатита с
EP2832871A4 (en) METHOD FOR ELIMINATING SILVER AND METALS ADDED BY ACTIVATED CARBON AND METHOD FOR RECOVERING SILVER AND OTHER METALS
IN2014CN03825A (es)
SE1630303A1 (en) A new method for predicting uric acid composition in urinarystones using routine single energy computer tomography

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BAXALTA INCORPORATED

FG Grant or registration